Impetigo
Table of Contents
- What Impetigo Is
- Pathophysiology and Bacterial Causes
- Non-Bullous Impetigo: Honey-Crusted Lesions
- Bullous Impetigo: Staphylococcal Exfoliative Toxins
- Ecthyma: Deep Ulcerative Form
- Risk Factors and Epidemiology
- Complications: Post-Streptococcal Glomerulonephritis
- Diagnosis
- Treatment: Topical and Oral Antibiotics
- Prevention and Decolonization
- Key Research Papers
- Connections
- Featured Videos
What Impetigo Is
Impetigo is the most common bacterial skin infection in children worldwide. It is a highly contagious, superficial infection of the epidermis — the outermost layer of the skin — that spreads easily through direct contact with infected skin or contaminated objects. Despite its alarming appearance, impetigo carries an excellent prognosis and resolves completely with appropriate treatment, leaving no scars in its most common form.
There are two principal clinical forms:
- Non-bullous impetigo — accounts for approximately 70% of cases; characterized by the hallmark golden-yellow honey-crusted lesions.
- Bullous impetigo — accounts for approximately 30% of cases; characterized by thin-walled fluid-filled blisters (bullae) on normal-appearing surrounding skin.
Impetigo affects people of all ages but predominates in children aged 2–5 years, who lack the protective immunity developed through repeated skin colonization with common bacteria. A 2015 systematic review by Bowen and colleagues estimated that more than 162 million children worldwide have impetigo at any one time, mostly in tropical, resource-poor settings, making it one of the most prevalent infectious diseases of childhood. It is a leading cause of school absenteeism globally.
Warm, humid climates dramatically increase prevalence — impetigo is endemic in tropical and subtropical regions, particularly in Indigenous and low-income communities where overcrowding and skin trauma from insect bites are common. In temperate climates, cases peak in summer and early autumn. Uncomplicated impetigo carries no mortality, but rare complications — notably post-streptococcal glomerulonephritis — require awareness and appropriate follow-up.
Pathophysiology and Bacterial Causes
Impetigo is caused by two principal gram-positive bacterial pathogens: Staphylococcus aureus and Streptococcus pyogenes (group A Streptococcus, GAS). The relative contribution of each organism has shifted over recent decades — S. aureus is now the dominant pathogen in most regions, capable of causing both non-bullous and bullous forms, while group A Streptococcus causes non-bullous impetigo only.
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an increasing concern in community-acquired impetigo, particularly in the United States, where community-associated MRSA (CA-MRSA) strains (most commonly USA300) have been identified in impetigo outbreaks among children, athletes, and prison populations.
Mechanism of infection — S. aureus bullous form: Certain phage group II strains of S. aureus produce exfoliative toxins ET-A and ET-B, which are serine proteases. These toxins cleave desmoglein 1 — the desmosomal cadherin protein that anchors keratinocytes together in the superficial epidermis (stratum granulosum). Cleavage of desmoglein 1 causes an intraepidermal split at this level, producing the characteristic thin-roofed bulla on normal-appearing skin. Crucially, because this process is enzymatic (proteolytic) rather than inflammatory, there is no surrounding erythema or induration — the bulla forms on skin that looks completely normal until rupture.
Mechanism of infection — S. aureus/group A Streptococcus non-bullous form: group A Streptococcus produces several virulence factors that facilitate superficial skin spread: streptokinase (dissolves fibrin clots), DNases, hyaluronidase (degrades connective tissue matrix), and M proteins (resist phagocytosis). These organisms exploit breaks in the skin barrier to establish infection in the epidermis.
Barrier disruption is the critical prerequisite: Intact skin is highly resistant to impetigo. Colonization and infection require a breach — from eczema/atopic dermatitis, varicella, herpes simplex, insect bites, abrasions, or lacerations. This is why impetigo so frequently complicates eczema flares in children.
It is important to distinguish impetigo from deeper bacterial skin infections: cellulitis involves the dermis and subcutaneous fat (presents with spreading erythema, warmth, and tenderness without primary bullae or honey crust), while erysipelas involves the upper dermis and superficial lymphatics (raised, well-demarcated, intensely red plaques). Impetigo is confined to the epidermis.
Non-Bullous Impetigo: Honey-Crusted Lesions
Non-bullous impetigo is the most common form, accounting for approximately 70% of all cases. Its hallmark is the golden-yellow "honey-crusted" lesion — a pathognomonic finding that allows confident clinical diagnosis at the bedside without laboratory confirmation in typical cases.
Clinical evolution:
- Small erythematous macule or papule appears at the site of skin trauma or pre-existing lesion.
- Rapidly evolves to a thin-walled vesicle or pustule (usually within hours to 1–2 days).
- The fragile vesicle/pustule ruptures spontaneously, releasing a serous or seropurulent exudate.
- The exudate dries to form the characteristic golden-yellow to amber honey-colored crust, which adheres firmly to the underlying erythematous base.
- Satellite lesions may develop at adjacent sites through autoinoculation (the child scratches the lesion and transfers organisms to other skin areas).
Favored locations: The face (perioral and perinasal regions are most common), followed by the extremities. Impetigo around the eye (periorbital) carries a risk of orbital cellulitis, which is treated as urgent.
Associated findings: Mild surrounding erythema is typical. Regional lymphadenopathy is common, particularly submandibular nodes with facial lesions. Systemic symptoms (fever, malaise) are typically absent — their presence can signal a deeper infection or bacteremia (bacteria in the blood).
Contagion: Highly contagious through direct contact with the serous/purulent exudate of active lesions. Fomite transmission (towels, bedding) is possible but less significant than direct contact. School and daycare exclusion policies commonly keep children with active lesions at home until 24 hours after antibiotic therapy starts.
Healing: When treated, lesions resolve without scarring — the infection is confined to the epidermis, which regenerates completely. Untreated lesions may persist for weeks but also eventually self-resolve in most immunocompetent individuals; however, untreated impetigo stays contagious longer and keeps the risk of complications open.
Causative organisms: S. aureus alone (most common in developed countries), mixed S. aureus + group A Streptococcus, or group A Streptococcus alone (more common in tropical/developing settings).
Bullous Impetigo: Staphylococcal Exfoliative Toxins
Bullous impetigo accounts for approximately 30% of impetigo cases and is caused exclusively by toxigenic strains of S. aureus (phage group II, particularly phage types 3A, 3B, 3C, 55, and 71). The defining pathological mechanism is the local action of exfoliative toxins ET-A and ET-B, which cleave desmoglein 1 in the stratum granulosum.
Distinguishing clinical features:
- Thin-walled, flaccid bullae arising on skin that appears completely normal (no surrounding erythema, induration, or inflammation at onset — this distinguishes bullous impetigo from other blistering conditions like herpes simplex or contact dermatitis, which show surrounding inflammation).
- Bullae begin clear and progress to cloudy yellow fluid as neutrophils accumulate.
- Bullae rupture easily, leaving a moist, red, glistening erosion with a peripheral "collarette" of scale — the remnant of the blister roof at the edge.
- Unlike non-bullous impetigo, there is no honey crust — the roof is too thin and the exudate too scant to form a substantial crust.
Favored locations: Trunk, buttocks, axillae, and intertriginous areas — moist skin folds facilitate blister formation. Less commonly the face and extremities.
Neonatal susceptibility: Neonates are particularly vulnerable to bullous impetigo because they lack antibodies against exfoliative toxins (maternal immunoglobulin G (IgG) wanes, and neonates have not yet developed their own immunity). Neonatal impetigo can cause nursery outbreaks.
Scalded Skin Syndrome (SSSS): When exfoliative toxins are produced in sufficient quantity to enter the bloodstream systemically — particularly in neonates, young infants, and immunocompromised adults — the toxins can cleave desmoglein 1 throughout the entire skin surface remotely from the primary infection site. This causes staphylococcal scalded skin syndrome: widespread superficial skin peeling resembling thermal burns, with a positive Nikolsky sign (gentle lateral pressure on normal skin causes the epidermis to slide off). SSSS requires hospitalization and intravenous (IV) antibiotics; mortality in children is low (~3%) but higher in immunocompromised adults (~60%).
Lower contagion than non-bullous: Paradoxically, bullous impetigo is somewhat less contagious than non-bullous — the intact bulla contains fewer organisms than the freely weeping exudate of ruptured non-bullous vesicles, and toxin-mediated blistering does not depend on high bacterial density at the transmission site.
Ecthyma: Deep Ulcerative Form
Ecthyma is the deepest form of impetigo, distinguished by its penetration through the epidermis into the dermis. While superficial impetigo heals without a scar, ecthyma invariably causes scarring because the dermis is involved in the destructive process.
Causative organism: S. pyogenes (group A Streptococcus) most commonly; sometimes S. aureus. The same organisms as non-bullous impetigo, but the infection goes deeper — usually because of delayed or absent treatment, host immunocompromise, impaired lymphatic drainage (lymphedema), or particularly virulent strains.
Clinical appearance: The pathognomonic finding is a "punched-out" ulcer with a violaceous (purple-gray) border, covered by a thick, adherent "oyster shell" crust. When the crust is lifted, a shallow ulcer with an erythematous base is revealed. The surrounding skin shows induration and erythema. Individual lesions are 0.5–3 cm in diameter.
Favored locations: Lower extremities, predominantly the legs and feet — a distribution explained by the prevalence of insect bites and trauma in these areas, plus dependent edema impeding local immune response. Also buttocks, perineum (particularly in incontinent patients).
Clinical course: Chronic and indolent — lesions persist for weeks to months if untreated, unlike superficial impetigo which may self-resolve. Healing is slow even with antibiotics (weeks), and scarring is the rule.
Risk factors:
- Insect bites and neglected traumatic wounds on the lower extremities
- Lymphedema (impairs local immune surveillance)
- Malnutrition and protein deficiency
- Diabetes mellitus (impaired wound healing + neutrophil dysfunction)
- Immunosuppression (human immunodeficiency virus (HIV), chemotherapy)
- Homelessness and skin-barrier compromise from environmental exposure
Complications: Ecthyma can progress to cellulitis, lymphangitis, and — in severely immunocompromised patients — bacteremia. In standard care the thick overlying crust is soaked and debrided so that antibiotic therapy can be effective. Ecthyma gangrenosum (caused by Pseudomonas aeruginosa, not streptococcus) is the key look-alike in neutropenic patients — it appears similar but is associated with systemic infection and carries high mortality.
Risk Factors and Epidemiology
Impetigo's estimated global burden of more than 162 million affected children at any one time (Bowen 2015) reflects the convergence of biological susceptibility, environmental factors, and social determinants of health.
Age: Children aged 2–5 years are most susceptible. The immature adaptive immune system has not yet developed memory responses against common skin pathogens, and behavioral factors (contact play, poor hand hygiene, nail biting, scratching insect bites) facilitate transmission and autoinoculation. Adolescents and adults can develop impetigo, particularly through contact sports (wrestling — "impetigo gladiatorum") or when skin barrier is disrupted.
Climate: Warm, humid climates dramatically increase prevalence. Heat and humidity promote bacterial growth on skin surfaces and increase insect biting activity. Tropical and subtropical regions — sub-Saharan Africa, South and Southeast Asia, the Pacific Islands, and northern Australia (particularly Indigenous communities) — bear a disproportionate burden. Temperate-climate seasonal peaks in late summer reflect similar thermodynamic factors.
Skin barrier disruption — the most critical risk factor:
- Atopic dermatitis (eczema): Most important risk factor in developed countries. The defective filaggrin-based skin barrier in eczema dramatically facilitates S. aureus colonization and invasion. A 2016 meta-analysis of 95 studies found S. aureus on 70% of affected (lesional) eczema skin, on 39% of unaffected skin and in the nose of 62% of people with eczema, who were far more likely to carry it than healthy controls (odds ratio 19.74).
- Varicella (chickenpox): A leading cause of secondary bacterial superinfection in unvaccinated children.
- Herpes simplex lesions, insect bites, lacerations, abrasions, scabies burrows.
Socioeconomic and environmental factors:
- Overcrowding in households, daycare centers, and schools — facilitates person-to-person transmission.
- Poor access to clean water — limits hand hygiene (the single most effective preventive measure).
- Contact sports (wrestling, rugby, football) — skin abrasions plus close body contact.
- Shared towels, razors, sports equipment.
Prevalence across communities: The 2015 Bowen systematic review pooled 82 population studies covering 145,028 children and found a median childhood prevalence of 12.3%; the highest burden was in underprivileged children from marginalised communities of high-income countries (median 19.4%).
Microbiological risk factors:
- Nasal carriage of S. aureus (present in ~30% of the general population) is a reservoir for skin inoculation — nares-to-skin autoinoculation explains many recurrent cases.
- Methicillin-resistant Staphylococcus aureus prevalence in the community (particularly USA300 in North America) is an increasing concern for treatment-refractory impetigo.
- Nephritogenic group A Streptococcus strains (M-types 49, 57, 59, 61) circulate in tropical/subtropical endemic settings and carry specific risk of post-streptococcal glomerulonephritis.
Complications: Post-Streptococcal Glomerulonephritis
Impetigo is generally a self-limited infection with excellent outcomes. However, one complication — post-streptococcal glomerulonephritis (PSGN) — deserves specific attention because it can cause permanent renal damage and is unique to group A Streptococcus-associated skin infection.
Post-Streptococcal Glomerulonephritis (PSGN):
PSGN is an immune complex-mediated glomerulonephritis triggered by specific nephritogenic strains of group A Streptococcus following skin infection. Key concepts:
- Group A Streptococcus skin infection, not S. aureus: Only group A Streptococcus (not S. aureus) causes PSGN. This makes accurate microbiological diagnosis important in endemic settings.
- Skin versus throat group A Streptococcus: Throat (pharyngeal) group A Streptococcus infection is the classic trigger of both rheumatic fever and PSGN. It has long been taught that skin infection causes PSGN only and not rheumatic fever, but newer evidence links skin infection to rheumatic fever too. In New Zealand data covering 1,866,981 throat and skin swabs, Māori and Pacific Peoples had a higher risk of acute rheumatic fever 8–90 days after a group A Streptococcus-positive skin swab (risk ratio 5.1) as well as after a positive throat swab (risk ratio 4.8), compared with a negative swab; the authors describe this as the first population-level evidence that group A Streptococcus skin infection can trigger rheumatic fever. This has major public health implications.
- Nephritogenic M-types: Not all group A Streptococcus strains cause PSGN — only those bearing specific nephritogenic M-proteins, particularly M-types 49, 57, 59, and 61, which are prevalent in tropical/subtropical regions (different strains from the pharyngeal nephritogenic type 12).
- Incubation period: PSGN develops 3–6 weeks after the skin infection (longer than the 1–3 weeks after pharyngeal infection) — this latency reflects the time for immune complex deposition and glomerular inflammation to develop.
- Clinical presentation: Hematuria (gross or microscopic, "coca-cola" colored urine), edema (periorbital, peripheral), hypertension, oliguria, proteinuria. The nephritic syndrome in its full form occurs in a minority; many cases present with asymptomatic urinary abnormalities only.
- Prognosis: In children, PSGN is usually self-limiting — the vast majority recover full renal function over weeks to months. Adults have worse outcomes, with a higher rate of progression to chronic kidney disease.
- Antibiotic treatment does NOT prevent PSGN: Unlike rheumatic fever (where early penicillin treatment prevents the complication), once group A Streptococcus skin infection is established, antibiotic treatment does not reliably prevent PSGN. Antibiotics are still indicated to treat the infection and reduce transmission.
Other complications:
- Cellulitis: Spread of infection from superficial impetigo to dermis/subcutaneous tissue; requires oral or intravenous antibiotics.
- Lymphadenitis: Infection of regional lymph nodes; may require incision and drainage if abscess forms.
- Bacteremia/septicemia: Rare in healthy immunocompetent children; more common in neonates and immunocompromised patients.
- Staphylococcal scalded skin syndrome (SSSS): Systemic dissemination of exfoliative toxins from bullous impetigo; primarily a risk in neonates (see Bullous section).
- Orbital cellulitis: Serious complication of periorbital impetigo; requires urgent ophthalmological evaluation and intravenous antibiotics.
Diagnosis
Impetigo is primarily a clinical diagnosis in typical presentations. The combination of golden honey-crusted lesions on the face of a child, or thin-walled bullae on normal-appearing skin, is sufficiently distinctive that laboratory confirmation is rarely required for initial management.
When to culture: Bacterial culture (swab from beneath a lifted crust — NOT from the surface, which yields contaminants) is indicated in:
- Recurrent or treatment-refractory impetigo (methicillin-resistant Staphylococcus aureus suspicion)
- Outbreak investigation in institutional settings (daycare, schools, military)
- Neonatal impetigo (to guide antibiotic selection and identify nursery reservoirs)
- Atypical presentations or diagnostic uncertainty
- Immunocompromised patients
Laboratory investigations: No routine bloodwork is required for uncomplicated impetigo. In outbreak settings with confirmed group A Streptococcus, urinalysis at 3–6 weeks after infection is reasonable to screen for asymptomatic PSGN (hematuria, proteinuria).
Differential diagnosis — key conditions to exclude:
- Tinea (ringworm): Annular scaly plaques without honey crust; potassium hydroxide (KOH) preparation reveals fungal hyphae; bacterial culture negative. Tinea capitis can mimic perinasal impetigo.
- Herpes simplex (HSV): Grouped vesicles on erythematous base (unlike bullous impetigo's bullae on normal skin); recurrent pattern; positive Tzanck smear (multinucleated giant cells) or polymerase chain reaction (PCR). Eczema herpeticum (Kaposi's varicelliform eruption) can be catastrophic — extensive grouped vesicles on eczematous skin require emergency treatment with acyclovir.
- Varicella (chickenpox): Viral prodrome (fever, malaise); simultaneous lesions at all stages (macule, papule, vesicle, crust); centripetal distribution; whole-body involvement.
- Contact dermatitis: History of allergen/irritant exposure; pruritic vesicular or papular rash; no honey crust; no regional lymphadenopathy; patch testing may clarify.
- Pemphigus vulgaris/foliaceus: Autoimmune blistering disease; positive Nikolsky sign; skin biopsy + direct immunofluorescence shows immunoglobulin G deposits at keratinocyte surfaces. Affects adults; rare in children.
- Bullous pemphigoid: Tense (not flaccid) bullae; elderly patients; positive indirect immunofluorescence; immunoglobulin G against hemidesmosomal proteins.
Treatment: Topical and Oral Antibiotics
Treatment selection depends on the extent of infection, clinical form (non-bullous vs. bullous), likelihood of methicillin-resistant Staphylococcus aureus, and patient age. The overarching principle: topical antibiotics for limited disease; oral antibiotics for widespread, bullous, ecthymatous, or recurrent infection.
Topical Antibiotics (Limited Non-Bullous Impetigo)
For patients with few lesions confined to a small area, topical antibiotics are the preferred approach — they achieve high local concentrations, have fewer systemic side effects, and cause less disturbance to the gut microbiome than oral antibiotics.
- Mupirocin 2% ointment: First-line topical agent. Applied to affected areas three times daily for 5 days. Highly effective against MSSA (methicillin-susceptible S. aureus) and group A Streptococcus. Limited activity against methicillin-resistant Staphylococcus aureus (approximately 15–20% of community methicillin-resistant Staphylococcus aureus strains are mupirocin-resistant where it has been used extensively). Gently soaking off the crusts before application lets the ointment reach the infected skin.
- Retapamulin 1% ointment: A pleuromutilin antibiotic; effective alternative to mupirocin; twice daily (BID) × 5 days. Also poor methicillin-resistant Staphylococcus aureus coverage. Not available in all countries.
- Fusidic acid 2% cream/ointment: Widely used in Europe and Australia (not available in the US). Effective against MSSA and group A Streptococcus. Resistance can emerge with monotherapy; used three times daily (TID) × 5–7 days.
- Ozenoxacin 1% cream: A newer topical antibiotic. In a randomised, double-blind trial of 411 patients aged 2 months and older, 5 days of twice-daily ozenoxacin gave clinical success in 112 of 206 patients (54.4%) against 78 of 206 (37.9%) on the inactive cream (P=.001), and cleared the bacteria in 87.2% against 63.9% after 2 days; 8 of 206 patients had side effects, none serious.
- Topical versus oral treatment: A 2012 Cochrane review of 68 trials with 5,578 participants found that topical antibiotics cured more people than placebo (risk ratio 2.24), that mupirocin and fusidic acid worked about equally well (risk ratio 1.03), and that topical mupirocin was slightly better than oral erythromycin (risk ratio 1.07); among oral antibiotics, penicillin did worse than erythromycin and cloxacillin. Side effects were more common with oral than with topical antibiotics, mostly stomach and bowel effects. Because few trials included people with extensive impetigo, the review found it unclear whether oral antibiotics are better in that group, and it noted growing resistance to commonly used antibiotics in the bacteria that cause impetigo worldwide.
Oral Antibiotics (Widespread, Bullous, Ecthymatous, or Methicillin-Resistant Staphylococcus Aureus Impetigo)
Oral antibiotics are used when lesions are too numerous or widespread for topical treatment, when bullous impetigo is present, for ecthyma, for recurrent impetigo, when topical therapy has failed, or when methicillin-resistant Staphylococcus aureus is confirmed or suspected.
For MSSA (non-MRSA) impetigo:
- Cephalexin (first-generation cephalosporin): 25–50 mg/kg/day in 3–4 divided doses × 7 days. First-line oral agent for MSSA impetigo in children. Well-tolerated, inexpensive, widely available.
- Dicloxacillin (penicillinase-resistant penicillin): 12.5–25 mg/kg/day divided four times daily (QID) × 7 days. Excellent MSSA coverage; poor palatability in children.
- Amoxicillin-clavulanate: Alternative for MSSA + GAS mixed infection; broader spectrum than needed for typical impetigo but useful when infection is recurrent or mixed flora suspected.
- Note: Plain amoxicillin is not active against most S. aureus — more than 90% of strains produce beta-lactamase and are resistant to it.
For methicillin-resistant Staphylococcus aureus impetigo:
- Trimethoprim-sulfamethoxazole (TMP-SMX): Highly effective against CA-MRSA (community-associated methicillin-resistant Staphylococcus aureus); 1–2 double-strength (DS) tablets or pediatric weight-based dosing BID × 7 days. Drug of choice when methicillin-resistant Staphylococcus aureus is confirmed or community methicillin-resistant Staphylococcus aureus prevalence is high. Note: poor group A Streptococcus coverage, so when group A Streptococcus is also suspected a beta-lactam is commonly added.
- Doxycycline: Effective against methicillin-resistant Staphylococcus aureus; 100 mg BID × 7 days. Labelled as not recommended under age 8 (permanent tooth staining). A 2015 study of 58 children who had short courses of doxycycline before age 8 (an average of 1.8 courses) found no tetracycline-type staining in any of them (0 of 58) and no significant difference in tooth shade or enamel defects compared with 213 children never given the drug. Used in older children and adults.
- Clindamycin: Effective against methicillin-resistant Staphylococcus aureus if susceptibility confirmed (inducible clindamycin resistance [iMLSB] is ruled out by a D-zone test). 10–20 mg/kg/day divided TID × 7 days.
Ecthyma: Same oral antibiotic regimens as above, extended to 7–10 days. In standard care, crusts are soaked and debrided at each dressing change to allow antibiotic penetration and removal of necrotic material.
Prevention and Decolonization
Primary prevention:
- Hand hygiene: The single most effective preventive measure. Hand washing with soap and water after touching lesions, before meals, and after diaper changes disrupts the contact-transmission chain.
- Cleaning skin wounds, insect bites, and abrasions and covering them with sterile dressings.
- Prompt and effective treatment of eczema/atopic dermatitis to restore the skin barrier — this is particularly important for children with recurrent impetigo complicating eczema.
- Not sharing towels, face cloths, razors, and sports equipment.
- Short fingernails in young children, which reduce scratching-related autoinoculation.
School/daycare exclusion policy: Exclusion policies commonly keep children with active impetigo lesions out of school, daycare, and contact sports until they have completed at least 24 hours of antibiotic therapy AND all lesions are crusted over. This 24-hour antibiotic window substantially reduces transmissibility; under these policies, exclusion beyond this point is generally not required.
Decolonization for recurrent impetigo: Patients with recurrent impetigo (3 or more episodes per year) or household clusters are commonly checked for nasal carriage of S. aureus — the primary reservoir that seeds repeated skin infections.
- Nasal mupirocin ointment: Applied to both nares twice daily for 5 days, then repeated monthly for 3–6 months in recurrent carriers. Eliminates nasal S. aureus carriage in ~80% of treated individuals. Most effective intervention for preventing recurrent S. aureus skin infections.
- Chlorhexidine gluconate body washes (2–4%): Daily wash × 5–14 days reduces skin surface S. aureus load. Part of the standard "decolonization bundle" for recurrent methicillin-resistant Staphylococcus aureus infections. The wash is typically left on the skin for 1 minute before rinsing and kept away from the eyes and mucous membranes.
- Household contacts: When the recurrence pattern suggests family transmission, decolonization treats all household members at the same time. Otherwise, successfully treated index patients are rapidly recolonized from untreated family contacts.
- Environmental decolonization: Laundering bed linens, towels, and clothing in hot water (>60°C/140°F) and cleaning shared surfaces with antiseptic solutions during active outbreaks.
No vaccine available: Despite decades of research, there is no licensed vaccine against S. aureus or group A Streptococcus impetigo. Vaccine development against group A Streptococcus is challenging because M-protein-based vaccines risk cross-reactive antibodies against cardiac tissue (molecular mimicry — the same mechanism underlying rheumatic fever). Research into non-M-protein group A Streptococcus vaccine candidates continues.
Key Research Papers
- Hay RJ et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014. — Search PubMed
- Moran GJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006. — PubMed PMID: 16914702
- Plano LR. Staphylococcus aureus exfoliative toxins: how they cause disease. J Invest Dermatol. 2004;122(5):1070-7. — PubMed PMID: 15140205
- Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. Australas J Dermatol. 2000;41(3):139-43. — PubMed PMID: 10954983
- Stevens DL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the IDSA. Clin Infect Dis. 2014. — PubMed PMID: 24973422
- Bowen AC et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One. 2015. — PubMed PMID: 26317533
- George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract. 2003;53(491):480-7. — PubMed PMID: 12939895
- Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2012;1(1):CD003261. — PubMed PMID: 22258953
- Sukumaran V, Senanayake S. Bacterial skin and soft tissue infections. Aust Prescr. 2016;39(5):159-163. — PubMed PMID: 27789926
- Nardi NM, Schaefer TJ. Impetigo. StatPearls. 2023. — PubMed PMID: 28613693
- Totté JE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2016;175(4):687-95. — PubMed PMID: 26994362
- Oliver J, Bennett J, Thomas S, Zhang J, Pierse N, Moreland NJ, Williamson DA, Jack S, Baker M. Preceding group A streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand. BMJ Glob Health. 2021;6(12):e007038. — PubMed PMID: 34887304
- Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, Hebert AA. Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo: a randomized clinical trial. JAMA Dermatol. 2018;154(7):806-813. — PubMed PMID: 29898217
- Todd SR, Dahlgren FS, Traeger MS, Beltrán-Aguilar ED, Marianos DW, Hamilton C, McQuiston JH, Regan JJ. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. J Pediatr. 2015;166(5):1246-51. — PubMed PMID: 25794784
- Sladden MJ, Johnston GA. Common skin infections in children. BMJ. 2004. — Search PubMed
PubMed Topic Searches
- PubMed: Impetigo bacterial skin infection children pathogenesis
- PubMed: Impetigo treatment mupirocin topical antibiotic
- PubMed: Impetigo MRSA community-acquired staphylococcus
- PubMed: Post-streptococcal glomerulonephritis impetigo GAS
- PubMed: Impetigo bullous staphylococcal exfoliative toxin
- PubMed: Impetigo epidemiology prevalence global burden
- PubMed: Impetigo ecthyma skin infection differential diagnosis
- PubMed: Impetigo prevention decolonization nasal mupirocin